Companion diagnostics and clinical development in oncology: a statistical perspective
Publié le
IDDI Complimentary Webinar on the need for integration of biomarker and IVD validation in clinical development Drug development in many…
Publié le
IDDI Complimentary Webinar on the need for integration of biomarker and IVD validation in clinical development Drug development in many…
Publié le
IDDI Complimentary Webinar on Immuno-Oncology Immuno-oncology is a buoyant field of research, with recently developed drugs showing unprecedented response rates…
Publié le
Adaptations to tumor response and progression criteria for immune therapies. Abstract Immuno-oncology is a buoyant field of research, with recently…
Publié le
What should companies look for when selecting a CRO clinicalpartner? Just one in ten drug candidates are successful in clinical…
Publié le
The development and qualification of biomarkers are keys to the future of drug development and precision medicine, particularly in oncology….
Publié le
IDDI Complimentary Webinar on Minimization LEARN ON: Minimization method including demonstration of some of the advantages of minimization over permuted…
Publié le
Transforming statistical data into a surrogate endpoint can enable comprehension of trial results sooner than usual, but few make the…
Publié le
IDDI in collaboration with Roche have identified why using disease-free survival as a primary endpoint in early breast cancer is…
Publié le
Free Webinar on Expansion Cohorts in Early Development of Anticancer Agents In this webinar we reviewed: The recent literature related…
Publié le
Free Live Webinar: Assessing Treatment Benefit in Immuno-Oncology In this webinar we reviewed key issues related to endpoints in immuno-oncology,…